Search Results - antoni+ribas

8 Results

Sort By:

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2018-748 A Method for Digital Pathology Using Augmented Reality

SUMMARYUCLA researchers in the Departments of Electrical Engineering and Computer Engineering have developed a novel method for automated image analysis of digital pathology slides.BACKGROUNDDigital pathology is an extremely powerful imaging tool in cancer research and clinical practices. Advancements in whole slide scanners has enabled complete digitization...

Published: 4/4/2024 | Inventor(s): Bahram Jalali, Antoni Ribas, Madhuri Suthar, Cejo Lonappan, Jia Chen, Theodore Nowicki

Keywords(s): Life Science Research Tools, Medical Devices and Materials, Medical Imaging, Microscopy And Imaging, Monitoring And Recording Systems

Category(s): Life Science Research Tools, Life Science Research Tools > Microscopy And Imaging, Medical Devices, Medical Devices > Medical Imaging, Medical Devices > Monitoring And Recording Systems

PAK4 in Cancer Immune Exclusion

Case 2018-209Researchers at the UCLA David Geffen School of Medicine have proposed that T cell tumor infiltration and the anti-tumor activity of anti-PD-1/PD-L1-based immunotherapy to be modulated through kinase PAK4 activity. BACKGROUNDThe p21-activated kinase 4 (PAK4) is a member of the PAK family of serine/threonine kinases, which are important...

Published: 7/19/2023 | Inventor(s): Antoni Ribas, Catherine Grasso

Keywords(s): Immunotherapy, Life Science Research Tools, Medical Devices and Materials, Oncology, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Medical Devices, Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology

2019-008 COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES

Researchers at the UCLA Department of Microbiology, Immunology, and Molecular Genetics have isolated T cell receptors (TCRs) specific for NY-ESO-1 epitopes presented by four MHC molecules, and developed novel approaches to extend TCR gene therapies targeting NY-ESO-1 using these TCRs.BACKGROUNDThe αβ T cell receptor (TCR) determines the unique...

Published: 7/19/2023 | Inventor(s): Owen Witte, Jami Witte, Michael Bethune, Antoni Ribas, Lili Yang, Jonathan Cebon, Katherine Woods, Ashley Knights

Keywords(s): Immunotherapy, Life Science Research Tools, Oncology, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Therapeutics, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

Genetic Mechanisms of Resistance to Anti-PD-1/L1 (UCLA Case No. 2016-075)

Genetic Mechanisms of Resistance to Anti-PD-1/L1SUMMARYUCLA researchers have identified a rare genetic mutation in the interferon receptor signaling pathway that can be used as a diagnostic to predict whether a patient will be or has become resistant to a cancer immunotherapy.BACKGROUNDClinical responses to programmed death‐1 (PD‐1) blockade therapy...

Published: 2/10/2024 | Inventor(s): Antoni Ribas, Daniel Shin, Angel Garcia-Diaz, Blanca Homet Moreno, Jesse Zaretsky

Keywords(s): Immunotherapy, Oncology Immunotherapy, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy

Methods for Predicting Response Patterns to Anti-PD-1 Therapy in Metastatic Melanoma (UCLA Case No. 2016-582)

SUMMARYDr. Roger Lo and colleagues in the Department of Medicine at UCLA have identified a method to predict a melanoma patient’s resistance to pembrolizumab and other immune checkpoint inhibitors.BACKGROUNDImmune checkpoint inhibitors are the most recent stars in cancer therapeutics: the first 4+ drugs in the category have received breakthrough...

Published: 2/14/2024 | Inventor(s): Roger Lo, Antoni Ribas, Willy Hugo, Jesse Zaretsky

Keywords(s):

Category(s): Diagnostic Markers, Therapeutics > Oncology > Oncology Immunotherapy

A Codon-Optimized Lentiviral Vector For Stem Cell Reprogramming (UCLA Case No. 2014-014)

A Codon-Optimized Lentiviral Vector For Stem Cell ReprogrammingSUMMARYUCLA researchers in the Department of Medicine and the Department of Surgery have developed a novel lentiviral vector that expresses a codon-optimized sequence of a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 as well as a positron emission tomography (PET)...

Published: 2/14/2024 | Inventor(s): Antoni Ribas, Richard Koya, Thinle Chodon

Keywords(s): Drug Delivery, Gene Editing Systems, Gene Therapy, Immunotherapy, iPS/stem cells, Life Science Research Tools, Plasmids / Vectors, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Life Science Research Tools > Plasmids/Vectors, Platforms > Drug Delivery, Therapeutics, Therapeutics > Gene Therapy And Editing, Therapeutics > Immunology And Immunotherapy, Therapeutics > Stem Cells And Regenerative Medicine > Ips Stem Cells

Treatment Of Melanoma With Ferroptosis Inducing Agents

Case 2017-879UCLA researchers in the Departments of Molecular and Medical Pharmacology and Medicine have developed a novel method to treat melanoma.BACKGROUNDImmune checkpoint blockade immunotherapy with anti-PD1 antibody is the preferred treatment for patients with metastatic melanoma that has resisted other therapies. However, there remains a subset...

Published: 7/19/2023 | Inventor(s): Thomas Graeber, Antoni Ribas, Nicolaos Palaskas, Lidia Robert, Jennifer Tsoi

Keywords(s):

Category(s): Therapeutics > Oncology